Reflecting recent work in the

Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets.

In this study, using pools of overlapping linear B-cell peptides, researchers report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognized by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor-binding domain. The other region, which is localized at the fusion peptide, could potentially function as a pan-SARS target.

Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralization capacities. Taken together, identification and validation of these neutralizing B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus.